Cullinan oncology to present first monotherapy clinical data for cln-619, a novel anti-mica/b antibody, at asco 2023

Cln-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor therapy

CGEM Ratings Summary

CGEM Quant Ranking